Accurate drug-drug interaction (DDI) prediction is essential to prevent adverse effects, especially with the increased use of multiple medications during the COVID-19 pandemic. Traditional machine learning methods often miss the complex relationships necessary for effective DDI prediction. This study introduces a deep learning-based classification framework to assess adverse effects from interactions between Fluvoxamine and Curcumin. Our model integrates a wide range of drug-related data (e.g., molecular structures, targets, side effects) and synthesizes them into high-level features through a specialized deep neural network (DNN). This approach significantly outperforms traditional classifiers in accuracy, precision, recall, and F1-score. Additionally, our framework enables real-time DDI monitoring, which is particularly valuable in COVID-19 patient care. The model’s success in accurately predicting adverse effects demonstrates the potential of deep learning to enhance drug safety and support personalized medicine, paving the way for safer, data-driven treatment strategies.